The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study

BACKGROUND: Acquired drug resistance to various tyrosine kinase inhibitor (TKI) inevitably develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). The present study aimed to evaluate the efficacy and safety of programmed cell death protein 1 (PD-1) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Chunyang, Wang, Zijian, Fu, Chengrui, Tao, Hengmin, Liu, Chengxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951015/
https://www.ncbi.nlm.nih.gov/pubmed/36846007
http://dx.doi.org/10.21037/atm-22-6272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951015/
https://www.ncbi.nlm.nih.gov/pubmed/36846007
http://dx.doi.org/10.21037/atm-22-6272

Ejemplares similares